RecruitingPhase 2NCT07215312

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Sponsor

Eli Lilly and Company

Enrollment

100 participants

Start Date

Oct 13, 2025

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new investigational drug called LY3938577 in people with type 2 diabetes who are already on daily basal insulin injections but whose blood sugar is not well controlled. Researchers want to see if this drug can improve blood sugar control. **You may be eligible if...** - You have type 2 diabetes - You are currently taking 20–55 units per day of basal insulin - Your HbA1c (a 3-month blood sugar average) is between 7.5% and 10.5% - Your BMI is between 20 and 35 kg/m² **You may NOT be eligible if...** - You have type 1 diabetes Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY3938577

Administered SC

DRUGDegludec

Administered SC

Locations(26)

Tucson Clinical Research Institute

Tucson, Arizona, United States

Encompass Clinical Research

Spring Valley, California, United States

University Clinical Investigators, Inc.

Tustin, California, United States

Tampa Bay Medical Research

Clearwater, Florida, United States

Encore Medical Research

Hollywood, Florida, United States

Clinical Research of Central Florida

Lakeland, Florida, United States

Encore Medical Research - Weston

Weston, Florida, United States

Iowa Diabetes and Endocrinology Research Center

West Des Moines, Iowa, United States

Washington University School of Medicine

St Louis, Missouri, United States

Accellacare - Wilmington

Wilmington, North Carolina, United States

AMR Clinical

Norman, Oklahoma, United States

Tribe Clinical Research, LLC

Greenville, South Carolina, United States

Holston Medical Group

Bristol, Tennessee, United States

Texas Diabetes & Endocrinology, P.A.

Austin, Texas, United States

Velocity Clinical Research, Dallas

Dallas, Texas, United States

Juno Research

Houston, Texas, United States

Southern Endocrinology Associates

Mesquite, Texas, United States

Consano Clinical Research, LLC

Shavano Park, Texas, United States

Texas Valley Clinical Research

Weslaco, Texas, United States

Chrysalis Clinical Research

St. George, Utah, United States

Cicemo Srl

Buenos Aires, Argentina

CIPREC

Buenos Aires, Argentina

Mautalen Salud e Investigación

Buenos Aires, Argentina

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Buenos Aires, Argentina

Instituto Centenario

CABA, Argentina

Instituto Médico Catamarca IMEC

Rosario, Argentina

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07215312

Related Trials

The eHealth Diabetes Remission Trial

NCT054910053 locations

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT070644731152 locations

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT056923881 location

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

NCT062513234 locations

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

NCT0743844421 locations